NCT00005918CompletedPhase 3
The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy
Bristol-Myers Squibb108 sites in 9 countries730 target enrollmentStarted: June 2000Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 730
- Locations
- 108
Study Overview
Brief Summary
The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).
Detailed Description
Patients are randomized to receive blinded stavudine extended release (d4T ER) or immediate release (d4T IR) formulation. Randomization is balanced by screening HIV viral load of less than 30,000 copies/ml or at least 30,000 copies/ml and by site. Patients also receive open-label efavirenz (EFV) and lamivudine (3TC). Efficacy is evaluated over 48 weeks of the dosing period and safety is evaluated over the entire dosing period (56 weeks).
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 12 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Study Sites (108)
Loading locations...
Similar Trials
Completed
Phase 2
Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected ChildrenHIV InfectionsNCT00000851National Institute of Allergy and Infectious Diseases (NIAID)198
Completed
Phase 3
Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)AIDSHIV InfectionsNCT00116298Bristol-Myers Squibb900
Completed
Phase 2
The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 WeeksHIV InfectionsNCT00001063National Institute of Allergy and Infectious Diseases (NIAID)200
Completed
Not Applicable
A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.HIV InfectionsNCT00002349Bristol-Myers Squibb40
Completed
Phase 3
Dose Optimisation of Stavudine for the Treatment of HIV InfectionAcquired Immune Deficiency SyndromeHuman Immunodeficiency VirusNCT02670772Willem Daniel Francois Venter1,077